The Effect of Orthognathic Surgery on Osteoprotegerin as Immunological Caliper of Bone Healing

Sara Soliman; Mamdouh Ahmed

doi:10.3889/oamjms.2016.123

Authors

Sara Soliman Oral and Maxillofacial Surgery Department, Faculty of Dentistry, Cairo University, Cairo
Mamdouh Ahmed Oral and Maxillofacial Surgery Department, Faculty of Dentistry, Cairo University, Cairo

DOI:

https://doi.org/10.3889/oamjms.2016.123

Keywords:

Cytokine, osteoprotegerin (OPG), bone remodelling, fracture healing, orthognathic surgery

Abstract

BACKGROUND: Osteoprotegerin (OPG) is considered to be the cytokine that plays an important role in the healing process. OPG regulates bone cell biology, osteoblastâ€“osteoclast, bone-immune cross-talk and maintenance of bone mass. It plays an important role in the development, induction, and repair of bone. Orthognathic surgery as multiples segmental osteotomies has been taken as a model surgery to assess the changes in osteoprotegerin levels in the post-operative bone healing period.

AIM: The aim of the study was to evaluate OPG as immunological caliper of bone healing.

MATERIAL AND METHODS: OPG was evaluated in nine patients seeking orthognathic surgery. Patients were examined and checked to be medically and immunologically free prior to surgery. Blood samples were collected immediate pre-operative as control group and for six weeks post-operative as study group.

RESULTS: Data were collected from nine consecutive patients. The results showed higher levels of OPG. it showed significant increase in the immediate post-operative value (p = 0.001) which started to increase gradually during the six weeks (p < 0.001).

CONCLUSIONS: Significant higher levels of OPG during the healing period of orthognathic surgery suggest the its use as immunological caliper of bone healing.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Kong YY, Boyle WJ, Penninger JM. Osteoprotegerin ligand: a regulator of immune responses and bone physiology. Immunol Today. 2000; 21: 495â€“502. https:/doi.org/10.1016/S0167-5699(00)01718-7 DOI: https://doi.org/10.1016/S0167-5699(00)01718-7

Wan M, Shi X, Feng X, Cao X. Transcriptional Mechanisms of Bone Morphogenetic Protein-induced Osteoprotegrin Gene Expression. J Biol Chem. 2001; 276: 10119â€“25. https:/doi.org/10.1074/jbc.M006918200 PMid:11139569 DOI: https://doi.org/10.1074/jbc.M006918200

Fahrleitner A, Prenner G, Leb G, Tscheliessnigg KH, Piswanger-SÃ¶lkner C, Obermayer-Pietsch B, et al. Serum osteoprotegerin is a major determinant of bone density development and prevalent vertebral fracture status following cardiac transplantation. J Inter Bone Miner Soc. 2003; 32: 96-106. https:/doi.org/10.1016/s8756-3282(02)00926-2 DOI: https://doi.org/10.1016/S8756-3282(02)00926-2

Ryser MD, Qu Y, Komarova SV. Osteoprotegerin in Bone Metastases: Mathematical Solution to the Puzzle. PLOS Comput Biol. 2012; 8: e1002703. https:/doi.org/10.1371/journal.pcbi.1002703 PMid:23093918 PMCid:PMC3475686 DOI: https://doi.org/10.1371/journal.pcbi.1002703

Kohli SS, Kohli VS. Role of RANKLâ€“RANK/osteoprotegerin molecular complex in bone remodeling and its immunopathologic implications. Indian J Endocrinol Metab. 2011; 15: 175-81. https:/doi.org/10.4103/2230-8210.83401 PMid:21897893 PMCid:PMC3156536 DOI: https://doi.org/10.4103/2230-8210.83401

Rogers A, Eastell R. Circulating osteoprotegerin and receptor activator for nuclear factor kappa B ligand: clinical utility in metabolic bone disease assessment. J Clin Endocrinol Metab. 2005; 90: 6323â€“31. https:/doi.org/10.1210/jc.2005-0794 PMid:16105967 DOI: https://doi.org/10.1210/jc.2005-0794

Theoleyre S, Wittrant Y, Tat SK, Fortun Y, Redini F, Heymann D. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodelling. Cytokine Growth Factor Rev. 2004; 15: 457â€“75. https:/doi.org/10.1016/j.cytogfr.2004.06.004 PMid:15561602 DOI: https://doi.org/10.1016/j.cytogfr.2004.06.004

Hofbauer LC, Schoppet M. Serum measurement of osteoprotegerin-clinical relevance and potential applications. Eur J Endocrinol. 2001; 145: 681â€“3. https:/doi.org/10.1530/eje.0.1450681 DOI: https://doi.org/10.1530/eje.0.1450681

Kotz S, Balakrishnan N, Read CB, Vidakovic B. Encyclopedia of statistical sciences. 2nd ed. Hoboken, NJ: Wiley-Interscience, 2006.

Kirkpatrick LA, Feeney BC. A simple guide to IBM SPSS statistics for version 20.0. Student ed. Belmont, Calif.: Wadsworth, Cengage Learning, 2013.

Giganti MG, Liuni F, Celi M, Gasbarra E, Zenobi R, Tresoldi I, et al. Changes in serum levels of TNF-alpha, IL-6, OPG, RANKL and their correlation with radiographic and clinical assessment in fragility fractures and high energy fractures. J Biol Regul Homeost Agents. 2012; 26: 671â€“80. PMid:23241117

Lee JS, Ryu CH, Moon NH, Kim SJ, Park SY, Suh KT. Changes in serum levels of receptor activator of nuclear factor-kB ligand, osteoprotegerin, IL-6 and TNF in patients with a concomitant head injury and fracture. Arch Orthop Trauma Surg. 2009; 129: 711-8. https:/doi.org/10.1007/s00402-008-0632-8 PMid:18427820 DOI: https://doi.org/10.1007/s00402-008-0632-8

Colombini A, Lombardi G, Galliera E, Dogliotti G, Randelli P, Meerssemann A, et al. Plasma and drainage fluid levels of soluble receptor activator of nuclear factor-kB (sRANK), soluble receptor activator of nuclear factor-kB ligand (sRANKL) and osteoprotegerin (OPG) during proximal humerus fracture healing. Int Orthop. 2011; 35: 777â€“82. https:/doi.org/10.1007/s00264-010-1088-3 PMid:20623281 PMCid:PMC3080502 DOI: https://doi.org/10.1007/s00264-010-1088-3

Freedman J, Goddard D. Elevated levels of transforming growth factor Î² and prostaglandin E2 in aqueous humor from patients undergoing filtration surgery for glaucoma. Can J Ophtamol. 2008; 43: 3. https:/doi.org/10.3129/i08-037 DOI: https://doi.org/10.3129/i08-037

KrÃ¤mer HH, Hofbauer LC, Szalay G, Breimhorst M, Eberle T, Zieschang K, Rauner M, Schlereth T, Schreckenberger M, Birklein F. Osteoprotegerin: A new biomarker for impaired bone metabolism in complex regional pain syndrome? PAIN. 2014;155(5):889-95. https:/doi.org/10.1016/j.pain.2014.01.014 PMid:24447513 DOI: https://doi.org/10.1016/j.pain.2014.01.014

Pape HC, Giannoudis PV, Krettek C, Trentz O. Timing of fixation of major fractures in blunt polytrauma: role of conventional indicators in clinical decision making. J Orthop Trauma. 2005; 19: 551â€“62. https:/doi.org/10.1097/01.bot.0000161712.87129.80 PMid:16118563 DOI: https://doi.org/10.1097/01.bot.0000161712.87129.80

Sen O, Gokcel A, Kizilkilic O, Erdogan B, Aydin MV, Sezgin N. The relation between serum levels of osteoprotegerin and postoperative epidural fibrosis in patients who underwent surgery for lumbar disc herniation. Neurol Res. 2005; 27: 452-55. https:/doi.org/10.1179/016164105X15631 PMid:15949247 DOI: https://doi.org/10.1179/016164105X15631

Crottia TN, Smith MD, Findlay DM, Zreiqatd H, Ahern MJ, Weedon H, et al. Factors regulating osteoclast formation in human tissues adjacent to peri-implant bone loss: expression of receptor activator NFkB, RANK ligand and osteoprotegerin. Biomater. 2004; 25: 565â€“73. https:/doi.org/10.1016/S0142-9612(03)00556-8 DOI: https://doi.org/10.1016/S0142-9612(03)00556-8

Nagasawa T, Kobayashi H, Kiji M, Aramaki M, Mahanonda R, Kojima T, et al. LPS-stimulated human gingival fibroblasts inhibit the differentiation of monocytes into osteoclasts through the production of osteoprotegerin. Clin Exp Immunol. 2002; 130: 338â€“ 44. https:/doi.org/10.1046/j.1365-2249.2002.01990.x PMid:12390325 PMCid:PMC1906523 DOI: https://doi.org/10.1046/j.1365-2249.2002.01990.x

Grzegorzewska AE, MÅ‚ot M. Serum osteoprotegrin level is lower in peritoneal dialysis patients than in hemodialysis ones. Annal Academ medic Bialost. 2004; 49: 193-6.